Press Releases

 Filter by Provider

Tulum, Mexico The future of holistic recovery has arrived. Nestled along the turquoise coastline of Tulum, a groundbreaking luxury rehab and ibogaine treatment center is setting a new global standard for safe, legal, and life-changing healing experiences. Designed for those seeking true transformation, this oceanfront sanctuary combines world-class medical care with spiritual depth — offering both ibogaine treatment and ayahuasca retreats in one integrated healing environment.

American Airlines, Citi and Mastercard today unveiled the Citi® / AAdvantage® Globe™ Mastercard®—a new entry in the travel credit card market that reimagines what mid-tier means with access to premium benefits. Designed to maximize the travel journey, the Citi® / AAdvantage® Globe™ Mastercard® offers four Admirals Club® Globe™ passes, each valid for 24 hours; more opportunities to earn AAdvantage® miles and Loyalty Points toward status, including a first-of-its-kind Flight Streak™ bonus; and over $750 in valuable travel and lifestyle benefits—all for an annual fee of $3501.

TORONTO, Oct. 19, 2025 (GLOBE NEWSWIRE) --  Rockcliffe Labs Inc. (“Rockcliffe Labs”), a Canadian biotechnology venture creation platform, announces the launch of its first dedicated program designed to transform breakthrough scientific discoveries into scalable companies. This launch establishes Rockcliffe Labs as the first institution of its kind in Canada, with a mandate to create 100 biotechnology and life sciences ventures over the next decade.

Hartgraves & the Adventure in Time!

RADNOR, PA - October 19, 2025 ( NEWMEDIAWIRE ) - The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) is currently investigating potential violations of the federal securities laws on behalf of investors of F5, Inc. ( NASDAQ: FFIV ) (“F5”).

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Denver, USA, October 19, 2025 -- October 10th, 2025 – NGY Football, a leading global smart sports investment platform, has announced that its registered user base has officially surpassed 6 million. This milestone marks a significant achievement, as the platform has rapidly evolved from an emerging player to a key participant in the industry within just a few years. Along with its swift user growth, NGY Football has consistently strengthened its technical research and development, security measures, and market expansion efforts, further solidifying its competitive edge in the global sports investment field.

RADNOR, PA - October 19, 2025 ( NEWMEDIAWIRE ) - The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) informs investors that a securities class action lawsuit has been filed against Lantheus Holdings, Inc. (“Lantheus”) ( NASDAQ: LNTH ) on behalf of those who purchased or otherwise acquired Lantheus securities between February 26, 2025, and August 5, 2025, inclusive (the “Class Period”). The lead plaintiff deadline is November 10, 2025.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

SaaSpedia is the #1 AI SEO agency for SaaS founders and startups. We help 120+ AI-driven brands get cited and trusted across ChatGPT, Gemini, Perplexity, and Google by mastering AEO, GEO, and LLM SEO. Backed by 3M+ GPT chats and 1.2M+ visitors, we turn SaaS websites into authority sources AI loves to recommend.

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced results from the Phase III HARMONi-6 trial, conducted in China and sponsored by our partner, Akeso, Inc. (HKEX Code: 9926.HK), featuring the novel, potential first-in-class investigational bispecific antibody, ivonescimab. The data was presented today as part of the Presidential Symposium at the European Society for Medical Oncology 2025 Congress (ESMO 2025) in Berlin, Germany.

RADNOR, PA - October 19, 2025 ( NEWMEDIAWIRE ) - The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) informs investors that a securities class action lawsuit has been filed against Fortinet, Inc. (“Fortinet”) ( NASDAQ: FTNT ) on behalf of those who purchased or otherwise acquired Fortinet common stock between November 8, 2024, and August 6, 2025, inclusive (the “Class Period”). The lead plaintiff deadline is November 21, 2025.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

RADNOR, PA - October 19, 2025 ( NEWMEDIAWIRE ) - The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) informs investors that a securities class action lawsuit has been filed against Molina Healthcare, Inc. (“Molina”) ( NYSE: MOH ) on behalf of those who purchased or otherwise acquired Molina securities between February 5, 2025, and July 23, 2025, inclusive (the “Class Period”). The lead plaintiff deadline is December 2, 2025.

IGOTIN, the Rapid Campus Takeover App. Empowering Connection, Collaboration, and Community.

Median progression free survival (PFS) has not been reached in the cohort of patients with salivary gland cancer with PFS follow up suggesting a more than doubling of the benchmark PFS and a disease control rate of 91%

From real homeowner pain points to daily comfort: human-centered engineering, motorized pergola controls, AAMA 2605 powder coating, and made-to-fit customization make luxury pergola features attainable.

Initial results from the dose escalation part of the first-in-human phase 1/2 trial of DS-3939 demonstrated promising clinical activity in patients with previously treated advanced solid tumors refractory to standard treatment. These data were presented today during a proffered paper session (917O) at the 2025 European Society for Medical Oncology (#ESMO25).

Study finds Skechers Arch Fit 2.0 superior to ASICS for senior walking shoes, offering better support at lower prices. Findings align with Healthfit Publishing's 49-day walking program designed for seniors with joint concerns.

Results from the phase 2 (dose optimization) part of the REJOICE-Ovarian01 phase 2/3 trial showed that raludotatug deruxtecan (R-DXd) demonstrated clinically meaningful response rates in patients with recurrent platinum-resistant ovarian, primary peritoneal or fallopian tube cancer. These data were presented today during a late-breaking proffered paper session (LBA42) at the 2025 European Society for Medical Oncology (#ESMO25) Congress.

Gilead Sciences, Inc. (Nasdaq: GILD) will present new findings from its antiviral research and development programs at IDWeek, taking place October 19-22 in Atlanta, GA. Data from 34 presentations across HIV, respiratory viruses, viral hepatitis, and viruses of pandemic potential including six oral presentations underscore Gilead’s leadership in advancing antiviral science and its ongoing efforts to bring forward innovative solutions for people and communities most affected by infectious diseases.

CAMBRIDGE, MA / ACCESS Newswire / October 19, 2025 / CAMBRIDGE, MA / ACCESS Newswire / October 19, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced data regarding two of its investigational influenza candidates will be presented at IDWeek 2025, October 19-22, 2025, in Atlanta, GA. The details of the presentations are as follows:

SOUTH SAN FRANCISCO, Calif., Oct. 19, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced that the Company plans to report topline data from the Phase 2 clinical trial of RPT904 (JYB1904) in patients with Chronic Spontaneous Urticaria (CSU) conducted by its partner, Shanghai Jeyou Pharmaceutical Co., Ltd. (Jeyou), formerly called Shanghai Jemincare Pharmaceutical Co., Ltd., in a premarket press release and webcast on Monday, October 20, 2025.RAPT will host a webcast conference call accompanied by a slide presentation on Monday, October 20, 2025 at 8:30 a.m. ET. To join the conference call via phone and participate in the live Q&A session, please pre-register online here to receive a telephone number and unique passcode required to enter the call. The live webcast and audio archive of the presentation may be accessed on the RAPT Therapeutics website at https://investors.rapt.com/events-and-presentations.

WOBURN, Mass., Oct. 19, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced data from a new ad hoc analysis from the IGNYTE phase 2 cohort of RP1 plus nivolumab was presented by Caroline Robert, M.D., Ph.D., at the European Society for Medical Oncology (ESMO) Congress 2025 being held in Berlin (Poster 1644P).

Interviews with fifty failed startup managers reveal that most collapses stemmed from weak leadership, not poor ideas. The findings highlight seven recurring management mistakes and emphasize that effective leadership is a learned skill, essential for building clarity, trust, and lasting team success.

BlockWoods is a leading Crypto Marketing agency with creative marketing experts to scale your business. Join hands with us to emerge as an iconic brand.

This thrilling first-person murder mystery by the author of two Amazon #1 best-sellers is written in past tense - but is set in the future at America’s Sestercentennial.

Dubai, UAE, October 19, 2025 -- ChillPlay Games today announced a significant milestone for its mobile title Over Hit: Hero Fight, which has surpassed 50,000 downloads on Google Play. Coinciding with this momentum, the studio released a major technical update that rebuilds the game from the ground up on a modular engine architecture based on Unity 6 and debuts AI Node, a new in-house module currently in beta. AI Node is powered by Claude AI by Anthropic and leverages the Model Context Protocol (MCP) during the game assembly process to deliver smarter enemies and more coherent level design.

Positive results from the TROPION-Breast02 Phase III trial showed DATROWAY® (datopotamab deruxtecan-dlnk) demonstrated a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival (OS) and progression-free survival (PFS) compared to investigator's choice of chemotherapy as 1st-line treatment for patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) for whom immunotherapy was not an option.

Owen Hanson, a former University of Southern California football player who received a 21-year federal sentence for drug trafficking, has launched a new website to share his redemption story and provide resources for people seeking to rebuild their lives.

Tanjong Malim, home to Proton Cars and upcoming BYD EV production, is adding a world-class AI-powered data centre at Sungai Samak Estate. This Malaysia Data Centre project supports Southeast Asia’s manufacturing growth, sustainability goals, and hyperscaler ambitions—offering unrivalled efficiency, connectivity, and expansion potential.

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual Meeting. The data demonstrated a progression-free survival (PFS) benefit for patients who experienced disease progression while on or after taking a PARP inhibitor (PARPi), a patient population with particularly poor prognosis. The presentation slides can be found here. The company also announced expansion of the Phase 2 BELLA trial in a poster session at ESMO, found here.

São Paulo / New York, 2025 — As a global asset management firm committed to bridging traditional finance and the digital future, Chainvest Gestora de Recursos Ltda. is driving the compliant development and inclusive adoption of blockchain finance and digital asset management across Latin America. At the heart of this mission stand two key leaders — João Pedro and Mariana Silva — whose extensive international investment banking and digital asset management experience form the strategic core of Chainvest’s global growth.

New York — 2025. The global landscape of blockchain finance and digital asset management welcomes a new force. Headquartered in New York, Chainvest Gestora de Recursos Ltda. officially announces its entry into the Brazilian market, marking the beginning of its strategic expansion across Latin America. This move represents a new chapter in the integration of digital finance with the global economy and underscores the company’s commitment to compliance and democratizing blockchain-based investment opportunities in the region.

Faeth Therapeutics today announced results from the international DICE trial, a randomized phase 2 study of sapanisertib (TAK228) plus weekly paclitaxel versus paclitaxel alone in women with platinum-resistant or recurrent epithelial ovarian or fallopian tube cancer. The trial was selected for a Late-Breaking Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2025 and met its pre-ordained statistical design and there is sufficient evidence of a positive signal to justify a larger phase 3 design.

Have you ever considered how you would appear if you were to wear someone else’s face? Or, would you rather effortlessly create some realistic, fun, and entertaining face swaps? Or Face swap Video is exactly what you need. You can swap faces in photos, memes, avatars, and even famous works of art with just a […]

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK-pathway-driven cancers, today announced positive, updated efficacy and safety data from partner GenFleet Therapeutics’ Phase 1/2 monotherapy study in China of GFH375, an oral KRAS G12D (ON/OFF) inhibitor (VS-7375 outside of China) for patients with KRAS G12D mutant advanced pancreatic ductal adenocarcinoma (PDAC). Among 59 heavily pre-treated patients with advanced disease, who received two or more prior lines of therapy, an overall response rate (ORR) of 41% was achieved at the monotherapy recommended Phase 2 dose (RP2D) of 600 mg daily (QD). The updated data were featured in a late-breaking abstract for oral presentation by GenFleet Therapeutics at the European Society for Medical Oncology (ESMO) Congress 2025 on October 19, 2025, in Berlin, Germany.

Pfizer Inc. (NYSE: PFE) and Astellas Pharma U.S. Inc. (Head of Commercial: Mike Petroutsas, "Astellas") today announced final overall survival (OS) results from the Phase 3 EMBARK study evaluating XTANDI® (enzalutamide), in combination with leuprolide and as monotherapy, in men with non-metastatic hormone-sensitive prostate cancer (nmHSPC; also known as nonmetastatic castration-sensitive prostate cancer or nmCSPC) with biochemical recurrence (BCR) at high risk for metastasis. For the key secondary endpoint of OS, XTANDI plus leuprolide reduced the risk of death by 40.3% compared to leuprolide alone (Hazard Ratio [HR]: 0.597; 95% Confidence Interval [CI], 0.444-0.804; p=0.0006), making this the first and only androgen receptor inhibitor-based regimen to demonstrate an OS benefit in nmHSPC with high-risk BCR.1 The 8-year overall survival was 78.9% (95% CI, 73.9% to 83.1%) among patients receiving XTANDI plus leuprolide and 69.5% (95% CI, 64.0% to 74.3%) among patients taking leuprolide alone.1 A numerical improvement in OS with XTANDI as monotherapy compared to leuprolide alone (HR: 0.83 [95% CI, 0.63-1.095; p=0.1867) did not reach statistical significance.1 These data are being presented today in an oral presentation at the European Society for Medical Oncology (ESMO) Congress in Berlin, Germany and have been simultaneously published in The New England Journal of Medicine.

Tubulis today announced positive early clinical data from its NAPISTAR1-01 Phase I/IIa study (NCT06303505) in a late-breaking oral presentation at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany. Principal Investigator, Dr. Antonio González-Martín, Director Medical Oncology Department and Cancer Center Director at Clínica Universidad de Navarra, presented the results of Tubulis’ lead antibody-drug conjugate (ADC), TUB-040, in platinum-resistant high-grade serous ovarian cancer (PROC-HGSOC), with a focus on dose levels 1.67 – 3.3 mg/kg. This is the first clinical data to validate Tubulis’ proprietary Tubutecan technology, establishing clear proof of concept for the company’s most advanced ADC targeting NaPi2b.

October 19, 2025 -- The Crisis of the Sister City Mission: Transparency, Accountability, and the Public Trust

October 19, 2025 -- Amid the swirl of new titles and industry deals at the 2025 Frankfurt Book Fair, one event stood apart for its soul-searching depth: the inaugural Xuemo World Literature Forum, themed "Eternal Love: Creating Meaning in the Void."

Positive results from the TROPION-Breast02 phase 3 trial showed DATROWAY® (datopotamab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival (OS) and progression-free survival (PFS) compared to investigator's choice of chemotherapy as first-line treatment for patients with locally recurrent inoperable or metastatic triple negative breast cancer (TNBC) for whom immunotherapy was not an option. These late-breaking results will be presented today during a proffered paper session (LBA21) at the 2025 European Society for Medical Oncology (#ESMO25) Congress.

Pfizer Inc. (NYSE: PFE) today announced updated follow-up results from the single-arm Phase 2 PHAROS trial evaluating BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) for the treatment of adults with metastatic non-small cell lung cancer (mNSCLC) with a BRAF V600E mutation. In treatment-naïve patients, the median overall survival (OS) was 47.6 months (95% confidence interval [CI], 31.3, not estimable) after a median follow-up of 52.3 months. In previously treated patients, the median OS was 22.7 months (95% CI, 14.1, 32.6), after a median follow-up of 48.2 months. The four-year OS rates were 49% (95% CI, 35, 62) and 31% (95% CI, 16, 47) for treatment-naïve and previously treated patients, respectively. These data, from pre-specified secondary trial endpoints, will be presented today in an oral presentation (1849MO) at the 2025 European Society for Medical Oncology (ESMO) Congress in Berlin, Germany, and have been simultaneously published in the Journal of Clinical Oncology.

Gilead Sciences, Inc. (Nasdaq: GILD) today shared positive data from the Phase 3 ASCENT-03 study demonstrating a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) for Trodelvy® (sacituzumab govitecan-hziy) compared to chemotherapy as first-line treatment in patients with metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitors. These findings will be presented today during a late-breaking oral session at the 2025 European Society for Medical Oncology (ESMO) Congress (Abstract #LBA20) and simultaneously published in The New England Journal of Medicine.

SAN FRANCISCO, Oct. 19, 2025 (GLOBE NEWSWIRE) -- Arbrest, a rising DTC home furnishing brand, today announced the launch of its independent website (www.arbrest.com). Guided by its “Gentle Design” philosophy, Arbrest blends natural materials with modern aesthetics to create furniture that gives homes room to breathe, shift, and settle. The brand’s vision, “Where Nature Rests, Life Finds Its Rhythm,” is to help every household find its own rhythm of living.

Based Eggman | $GGs Crypto Presale | Gaming & Social - Fi on Base Layer-2.

Alpha Wealth Group introduces enhanced wealth structuring solutions aimed at securing multi-generational prosperity for high-net-worth clients in a rapidly evolving financial world.

The founder of Le Muse Magazine consolidates her global presence and redefines the creative power of the region at major international fashion weeks.

Divy Fashion Mart pioneers a groundbreaking "investment shopping" model, allowing consumers to earn equity with every purchase, revolutionizing retail.